Business Wire

Ipsen to Present 12 Abstracts at the 11 th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35 th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER) 1-13


Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 12 abstracts during the 11th World Congress for Neurorehabilitation (WCNR), taking place virtually between 7-11 October 2020.1-13

Spasticity is a disabling condition in adults and children, characterized by velocity-dependent muscle hyperactivity. It is the consequence of many neurological diseases, such as stroke, multiple sclerosis (MS), Traumatic Brain and Spinal Cord Injury and Cerebral Palsy. Spasticity can have significant impact on the lives of patients, causing multi-level disability, including impaired walking and hand use, pain, disfigurement and contractures.14 Cervical dystonia is a rare disorder of unknown origin in most of the primary cases, characterized by involuntary contractions of the neck muscles.15

“Our goal at Ipsen is to put the patient at the center of everything we do; our research aims to understand and address the unmet needs and support care optimization by providing tailored therapeutic solutions that help patients regain more control of their lives,” said Dr. Andreas Lysandropoulos, Vice President Medical Affairs Neuroscience, Ipsen.

Overview of Ipsen presentations at the WCNR 2020 Congress:1-12

Abstract title

Poster number/Session timing (CEST)

Differences in the patient experience of spasticity management with botulinum toxin type A: A comparison of European versus American survey findings

Poster number: P0274

Session timing: 09.00-20.00 7/10/2020

An international, multicentre, observational, longitudinal study to assess the effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity: The AboLiSh study

Poster number: P0275

Session timing: 09.00-20.00 7/10/2020

Longitudinal goal attainment with integrated upper limb spasticity management including botulinum toxin A: Primary results from the ULIS-III study

Poster number: P0276

Session timing: 09.00-20.00 7/10/2020

Real-life data on the time to retreatment with botulinum toxin A in upper limb spasticity management

Poster number: P0278

Session timing: 09.00-20.00 7/10/2020

Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: an ethnographic study

Poster number: P0279

Session timing: 09.00-20.00 7/10/2020

7-Year Experience from the Ixcellence Network®: An International Innovative Educational Program To Improve Cervical Dystonia And Spastic Paresis Management

Poster number: P0301

Session timing: 09.00-20.00 7/10/2020

Importance of Training and Practice Regarding Rehabilitation Approaches Integrated with Botulinum Neurotoxin-A Guided Injection in Cervical Dystonia & Spastic Paresis: results from the INPUT survey

Poster number: P0302

Session timing: 09.00-20.00 7/10/2020

Efficacy and safety of abobotulinumtoxinA in pediatric lower limb spasticity: 2nd interim results from a phase IV, prospective, observational, multicenter study

Poster number: P0304

Session timing: 09.00-20.00 7/10/2020

Development of the Hygiene Extension Limb position Pain (HELP) Tool to monitor waning of clinical efficacy in patients with spasticity or cervical dystonia treated with botulinum toxins

Poster number: P0306

Session timing: 09.00-20.00 7/10/2020

Economic analysis of real-world use of BotulinumtoxinA products (BoNTA) for treatment of adult upper limb spasticity (AUL)

Poster number: P0311

Session timing: 09.00-20.00 7/10/2020

AbobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: Efficacy and safety findings from an international, Phase 3, pivotal study

Poster number: P0503

Session timing: 09.00-20.00 7/10/2020

Neuromodulation of cortical beta oscillatory activity following botulinum injection in post-stroke.

Oral presentation number: OP068 Session timing: 9.45 11/10/2020


Notes to editors

About spasticity

Spasticity is estimated to affect more than 12 million people worldwide.16 It is a condition in which certain muscles are continuously contracted causing stiffness or tightness of the muscles, which can interfere with normal movement, gait and speech.17 Spasticity is usually caused by damage to the parts of the brain or spinal cord that control voluntary movement,17-18 leading to a change in the balance of signals between the nervous system and the muscles which leads to increased activity in the muscles.17 Spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma and metabolic diseases can all cause spasticity.18 Spasticity is experienced by approximately 34% of stroke survivors within 18 months following a stroke.19

About cervical dystonia

Cervical dystonia (CD), also known as spasmodic torticollis, is a movement disorder in which involuntary muscular contractions occur primarily in the neck muscles.15,20 This can cause the head to turn to one side or to be pulled backward or forward.15,21 CD is relatively uncommon, affecting 57 to 280 people per million.22 It can occur at any age, although symptoms generally appear in middle age, often beginning slowly and usually reaching a plateau over a few months or years.23 The degeneration of the spine, irritation of nerve roots or frequent headaches can make CD particularly painful.23 In most cases the cause is unknown and no cure exists.22

About Dysport®

Dysport® (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. AbobotulinumtoxinA has marketing authorization in more than 85 countries and more than 30 years of clinical experience.

The detailed recommendations for the use of Dysport are described in the Summary of Product Characteristics (SmPC) for Dysport (300 units) Powder and Dysport (500 units) Powder, and the U.S. Prescribing Information (PI).

NOTE: Dysport® labels and approved indications may vary from country to country.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit

Ipsen’s Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations, and the outcome of this study or other studies. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of 6 pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2019 Universal Registration Document available on its website (


  1. Jacinto et al., WCNR 2020. Differences in the patient experience of spasticity management with botulinum toxin type A – a comparison of European versus American survey findings.
  2. Esquenazi et al., WCNR 2020. An international, multicentre, observational, longitudinal study to assess the effectiveness of abobotulinum toxin A injections for adult lower limb spasticity – The AboLiSh study.
  3. Turner-Stokes et al., WCNR 2020. Longitudinal goal attainment with integrated upper limb spasticity management including botulinum toxin A – Primary results from the ULIS-III study.
  4. Jacinto et al., WCNR 2020. Real-life data on the time to retreatment with botulinum toxin A in upper limb spasticity management.
  5. Jacinto et al., WCNR 2020. Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle – an ethnographic study.
  6. Dursun et al., WCNR 2020. 7-year experience from the Ixcellence Network® – an international innovative educational program to improve cervical dystonia and spastic paresis management.
  7. Jacinto et al., WCNR 2020. Importance of training and practice regarding rehabilitation approaches integrated with botulinum neurotoxin-A guided injection in cervical dystonia & spastic paresis – results from the INPUT survey.
  8. Gormley et al., WCNR 2020. Efficacy and safety of abobotulinum toxin A in pediatric lower limb spasticity – 2nd interim results from a phase IV, prospective, observational, multicenter study.

  9. Patel et al., WCNR 2020. Development of the Hygiene Extension Limb position Pain (HELP) tool to monitor waning of clinical efficacy in patients with spasticity or cervical dystonia treated with botulinum toxins.
  10. Schnitzler et al., WCNR 2020. Economic analysis of real-world use of Botulinum toxin A products (BoNTA) for treatment of adult upper limb spasticity (AUL).
  11. Dabrowski, et al., WCNR 2020. Efficacy and safety of abobotulinum toxin A for upper limb spasticity in children with cerebral palsy.
  12. Chalard et al., WCNR 2020. Neuromodulation of cortical beta oscillatory activity following botulinum injection in post-stroke.
  13. WCNR Virtual Congress 2020: Abstracts. WCNR. Accessed: October 2020. Available:
  14. Royal College of Physicians, British Society of Rehabilitation, “Spasticity in adults: management using botulinum toxin. National Guidelines”; 2018
  15. Mayo Clinic. Cervical Dystonia. Available at Accessed October 2020.
  16. John Hopkins Medicine. Spasticity. Available at: Accessed October 2020
  17. American Association of Neurological Surgeons. Spasticity. Available at: Accessed October 2020
  18. American Association of Neurological Surgeons. Movement Disorders. Available at: October 2020
  19. Kuo C. Post-stroke Spasticity: A review of epidemiology, pathophysiology, and treatments.Int J Gerontol 2018;12:280-284.
  20. Claypool D, et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Movement Disorders 1995;10: 608-614.
  21. National Institute of Neurological Disorders and Stroke. Dystonias Fact Sheet. Available at Accessed October 2020.
  22. Castelão M, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2017;12:CD003633.
  23. American Association of Neurological Surgeons. Dystonia. Available at Accessed October 2020.

Contact information

Jess Smith
Senior Director, Global Franchise Communications and UK & Ireland Hub
+44 (0) 7557 267634

Annie Phelps
Global Franchise Communications Manager, Specialty Care
+44 (0) 7736 619 613

Financial Community
Eugenia Litz
Vice President, Investor Relations
+44 (0) 1753 627721

Myriam Koutchinsky
Investor Relations Manager
+33 (0)1 58 33 51 04

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment21.1.2021 23:12:00 CETPress release

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV He

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)21.1.2021 22:30:00 CETPress release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde

Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 17:45:00 CETPress release

Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this

NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 17:40:00 CETPress release

NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr

Andersen Global Strengthens African Platform with Kashadah & Co.21.1.2021 15:30:00 CETPress release

Andersen Global continues to reinforce its competitive edge in the African region through a Collaboration Agreement with full-service tax firm Kashadah & Co. in Libya. Kashadah & Co., founded in 1974 by Office Managing Partner Abdussalam Kashadah, provides a wide range of services including tax planning, consultation and compliance, assurance and business advisory, social security arrangements, company registration, receivership and liquidation. The Tripoli-based firm’s clients include oil companies, banks and government institutions. “We are delighted for this opportunity to collaborate with like-minded professionals who share our philosophies and vision of delivering best-in-class services with a client-focused approach,” Abdussalam said. “We have a long-standing, working relationship with collaborating firm Jelil Bouraoui & Associates in Tunisia, and look forward to working with the member and collaborating firms in the region and globally.” Andersen Global Chairman and Andersen CEO

Nottinghamshire County Council Renews Support Agreement With Rimini Street for Its Mission-Critical SAP Applications21.1.2021 15:00:00 CETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Nottinghamshire County Council (NCC) has renewed its agreement with Rimini Street for Support of its SAP ECC 6.0 and SAP Business Objects software. NCC first switched to Rimini Street in 2017, achieving substantial savings in maintenance fees over the last three years, as well as related savings in avoided upgrades, process efficiencies and customization support, included at no additional charge. At a time of significant strain on public sector budgets, NCC renewed its agreement with Rimini Street to continue to achieve these essential savings as the local authority seeks to drive efficiencies in its back-office IT systems. Additionally, NCC has the reassurance that their software systems will be supported for a guaranteed minimum of 15 years from the time they swi

Alvarez & Marsal Announces 2021 Managing Director Promotions21.1.2021 15:00:00 CETPress release

Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 37 professionals from across Benelux, Brazil, Germany, India, Italy, Sweden, the United Kingdom and the United States to the position of Managing Director. John Suckow, A&M’s Chief Operating Officer, stated, “For over 37 years, A&M professionals have delivered leadership, action and results to our clients. In this unique and challenging year, our leaders have not wavered, and we have achieved extraordinary professional growth and success. We congratulate all of our newly promoted Managing Directors and applaud their commitment to A&M's core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity.” Brazil Henrique Biscolla, São Paulo Eduardo Gallardo, São Paulo Emerson Santana, São Paulo Corporate Performance Improvement Tres Evans, Dallas Michael Nelson, Chicago Kristin Shelley, Dallas Global Disputes and Investigations Nikki Coles, London Europe - Performance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom